ContraFect (NASDAQ:CFRX) Research Coverage Started at StockNews.com
StockNews.com started coverage on shares of ContraFect (NASDAQ:CFRX – Free Report) in a report issued on Sunday. The brokerage issued a sell rating on the biotechnology company’s stock. ContraFect Stock Down 28.0 % CFRX opened at $0.05 on Friday. The company has a market cap of $535,000.00, a price-to-earnings ratio of 0.00 and a beta […]